Catalyst Brief

← Calendar

Readoutin 13d

Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair — Topotecan - usual

Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms.

Date
Dec 2026
Type
Readout
Indication
SCLC

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.